KPV: Research Profile and Protocol Guide

Overview

KPV is a naturally occurring tripeptide (Lys-Pro-Val) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). While the full alpha-MSH molecule (13 amino acids) activates melanocortin receptors causing pigmentation and other effects, the KPV fragment retains potent anti-inflammatory activity without melanocortin receptor binding or pigmentation effects. This makes KPV particularly interesting for inflammatory research where melanocortin side effects are undesirable. Research has demonstrated KPV's anti-inflammatory effects in models of colitis, skin inflammation, and systemic inflammatory conditions, primarily through inhibition of the NF-kB signaling pathway. The peptide has attracted significant interest in the gut health research community for its potential applications in inflammatory bowel conditions.

Mechanism of Action

KPV exerts anti-inflammatory effects primarily through direct inhibition of the NF-kB signaling pathway, independent of melanocortin receptor activation. The peptide enters cells and inhibits IKK (IkB kinase) activation, preventing nuclear translocation of NF-kB and subsequent transcription of pro-inflammatory cytokines including TNF-alpha, IL-1beta, and IL-6. Studies have also demonstrated that KPV can be transported across intestinal epithelial cells by the PepT1 transporter, enabling direct anti-inflammatory effects in gut tissue when administered orally. This transepithelial transport mechanism is particularly relevant for inflammatory bowel research applications.

Research Applications

Gut inflammation and colitis research (primary), skin inflammation (dermatitis, wound healing), systemic anti-inflammatory applications, IBD research models, oral peptide delivery research

Research Protocols

Safety Profile and Considerations

Derived from endogenous alpha-MSH - naturally occurring in the body. No significant adverse effects reported in preclinical studies. No melanocortin receptor activation at standard concentrations (no pigmentation effects). No human clinical trials published. Not FDA approved.

Storage and Stability

Lyophilized: -20C. Reconstituted: 2-8C, use within 30 days. See our storage and handling guide for comprehensive best practices.

Published Research

• Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of IBD. Inflamm Bowel Dis. 2008
  PMID: 18275070
• Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008
  PMID: 18926830
• Brzoska T, et al. Alpha-MSH and related tripeptides: biochemistry, anti-inflammatory effects. Endocr Rev. 2008
  PMID: 18436706

Search for additional KPV research on PubMed.

Where to Source KPV

Peptide purity is critical for research accuracy. We evaluate suppliers against our 100-point methodology.